ANDROMEDA BIOTECH LTD.
ANDROMEDA BIOTECH LTD.
Industry:
Biotechnology Clinical Trials Medical
Founded:
2007-01-01
Address:
Yavne, HaMerkaz, Israel
Country:
Israel
Status:
Closed
Contact:
+97289387777
Similar Organizations
Hiroshima Bio-Medical
Hiroshima Bio-Medical is a biotechnology company.
Huapont-Nutrichem
Huapont-Nutrichem Co. Ltd. is a Biotechnology Company.
Inbiopro Solutions Private Ltd
Inbiopro Solutions Private Ltd is a Biotechnology company.
Spark Biopharma
Spark Biopharma is a biotechnology company
Current Advisors List
More informations about "Andromeda Biotech Ltd."
Andromeda Biotech Company Profile 2024: Valuation, Investors ...
When was Andromeda Biotech founded? Andromeda Biotech was founded in 2007. Where is Andromeda Biotech headquartered? Andromeda Biotech is headquartered in Yavne, Israel. …See details»
Andromeda Biotech - Ownership and Business Overview - Mergr
Jun 12, 2014 Andromeda Biotech is a life science company. When was Andromeda Biotech founded? Andromeda Biotech was founded in 2007. Life Science M&A Summary in 2014. Out …See details»
Andromeda Biotech Ltd. acquired by Hyperion Therapeutics
Apr 24, 2014 Andromeda Biotech Ltd. Andromeda Biotech Ltd. is a Biotechnology company. Acquiring Organization: Hyperion Therapeutics Hyperion Therapeutics is a biopharmaceutical …See details»
Organization | Andromeda Biotech Ltd.
Andromeda Biotech Ltd. Report issue For profit Phase 3 Founded: Yavne Israel (2007)See details»
Andromeda Biotech Ltd.: Drug pipelines, Patents, Clinical trials
Explore Andromeda Biotech Ltd. with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, 2 news, Drug:DiaPep-277.See details»
Andromeda Biotech - Company Profile - Tracxn
Andromeda Biotech - Peptide-based drug for the treatment of type 1 diabetes. Acquired by Hyperion Therapeutics. Raised a total funding of $17.5M over 1 round from 2 investors. …See details»
Andromeda Biotech Ltd - Company Profile and News
Company profile page for Andromeda Biotech Ltd including stock price, company news, executives, board members, and contact informationSee details»
Andromeda Biotech - Overview, News & Similar companies
Andromeda Biotech Ltd., a subsidiary of Clal Biotechnology Industries Ltd. (TASE:CBI), is focused on the development of an innovative treatment for autoimmune diabetes. Andromeda's …See details»
Andromeda Biotech Ltd. - Crunchbase
Andromeda Biotech Ltd. is a Biotechnology company.See details»
Andromeda Biotech - Products, Competitors, Financials, …
Andromeda Biotech is focused on the development of an innovative treatment for autoimmune diabetes. Use the CB Insights Platform to explore Andromeda Biotech's full profile. …See details»
Hyperion Therapeutics to Broaden Orphan Disease ... - Fierce Biotech
BRISBANE, Calif., April 24, 2014 -- Hyperion Therapeutics announced today that it has entered into a definitive agreement under which it will acquire Andromeda Biotech Ltd., an Israel-based ...See details»
Hyperion Therapeutics Completes Acquisition of Andromeda
Jun 12, 2014 - Hyperion's Orphan Drug Pipeline Now Includes DiaPep277®, a First-in-Class Immunotherapy for New Onset Type 1 Diabetes, With Phase 3 Data Expected in the First …See details»
Andromeda Biotech Ltd. announced that it has received $10 …
Aug 15, 2012 Andromeda Biotech Ltd. announced that it has raised $10,000,000 from returning investors Teva Pharmaceutical Industries Limited and Clal Biotechnology Industries on August …See details»
Hyperion bets up to $570M on diabetes biotech Andromeda
Apr 24, 2014 Andromeda, a subsidiary of Clal Biotechnology, is due $12.5 million in cash and about $7.9 million in Hyperion stock up front, with $120 million tied to regulatory milestones …See details»
Andromeda Biotech Ltd. - Contacts, Employees, Board
Andromeda Biotech Ltd. is a Biotechnology company.See details»
DiaPep-277 - Drug Targets, Indications, Patents - Synapse
Andromeda Biotech Acquires DiaPep277 Rights From Teva Pharmaceutical Industries Limited YAVNE, Israel, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces …See details»
Hyperion Terminates Development of Immune Intervention
Sep 12, 2014 Twitter summary: Due to company misconduct by Andromeda, biotech co. Hyperion terminates development of immune intervention therapy for #T1D. On September 8, …See details»
Mystery U.S. pharma company circles Andromeda and its PhIII …
Feb 26, 2014 A couple of day ago, Israel's Andromeda Biotech bought back the worldwide rights to its Phase III diabetes therapy--DiaPep277 for Type 1 patients--from Teva for $72 million, to …See details»
Andromeda Biotech Initiates DIA-AID 2, a Confirmatory Phase 3 …
Jun 2, 2010 Andromeda Biotech Ltd. announced the initiation of its confirmatory phase III clinical study, DIA-AID 2 using DiaPep277®, Andromeda’s lead product, for the treatment of type 1 …See details»
DARZALEX® (daratumumab) SC-based regimens improve MRD
1 day ago New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with daratumumab SC were progression free at 4.5 years …See details»